A plant-based Covid-19 vaccine developed by Canadian pharmaceutical firm Medicago “very likely won’t be accepted” for emergency use approval by the World Health Organization because Medicago is ...

The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. A plant-based ...

(Reuters) -Canadian vaccine maker Medicago's COVID-19 vaccine, approved last month in Canada, is facing limited growth in the near-term after the World Health Organization said it would not review the ...

- Company's results continue to be amongst the best for influenza vaccine manufacturing technologies - QUEBEC CITY, June 30, 2011 /PRNewswire/ - Medicago Inc. (TSX: MDG) a biotechnology company ...

QUEBEC CITY--(BUSINESS WIRE)--Medicago, a biopharmaceutical company headquartered in Quebec City, began Phase I clinical trials for its plant-derived COVID-19 vaccine candidate yesterday, ...

QUÉBEC CITY, July 12, 2013 /CNW/ - Medicago Inc. (TSX: MDG; OTCQX: MDCGF), a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary ...

QUEBEC CITY, Quebec--(BUSINESS WIRE)--Medicago, a biopharmaceutical company headquartered in Quebec City, announced today that its vaccine candidate for COVID-19 induced a positive antibody response ...

QUEBEC CITY, March 12, 2020 /CNW/ - Medicago, a biopharmaceutical company headquartered in Quebec City, announced today that they have successfully produced a Virus-Like Particle (VLP) of the ...

Medicago will be shutting down its COVID-19 vaccine project in Quebec after its sole shareholder decided to no longer invest in the company, the company announced Thursday. With the Japan-based ...

RALEIGH, NC and Quebec City, Sept. 13, 2011 /PRNewswire via COMTEX/ -- Operations begin within eleven months of hosting groundbreaking ceremony- Medicago USA Inc., a wholly owned subsidiary of ...

"We are thrilled to see our COVID-19 vaccine candidate enter the Phase 1 trial, and we look forward to obtaining safety and immunogenicity results in October," said Nathalie Landry, Executive ...